Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ / shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Expenses:
Consulting (Note 11)	$ 30,500	$ 45,000
Research and development (Note 10)	2,180	84,203
Selling, general and administrative (Notes 9 and 11)	47,184	72,777
Stock-based compensation (Notes 7 and 11)	4,392	36,174
Loss from operations	(84,256)	(238,154)
Interest income	1,440	3,095
Net loss	(82,816)	(235,059)
Other comprehensive loss
Currency translation differences	(570)	(1,159)
Total comprehensive loss	$ (83,386)	$ (236,218)
Net loss per share - basic and diluted (in dollars per share)	$ (0)	$ (0)
Weighted average number of common shares outstanding – basic and diluted (in shares)	91,422,569	91,422,569